Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
8.680
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
August 13, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD.
Via
Talk Markets
MindMed's Q2 2023: One Of Biggest Players In The Space Sustains Faith In LSD's Multiple Path Ahead
August 07, 2023
Clinical-stage psychedelics biotech MindMed’s (NASDAQ: MNMD) unaudited financial results for the quarter ended June 30, 2023 look like this:
Via
Benzinga
What 9 Analyst Ratings Have To Say About Mind Medicine
August 04, 2023
Via
Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...
Via
Benzinga
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
July 30, 2023
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July:
Via
Talk Markets
The Latest Analyst Ratings for Mind Medicine
June 28, 2023
Via
Benzinga
Mind Medicine: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Earnings Outlook For Mind Medicine
May 03, 2023
Via
Benzinga
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
July 28, 2023
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
July 23, 2023
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug...
Via
Talk Markets
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 18, 2023
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.
Via
Benzinga
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD
July 14, 2023
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD.
Via
Talk Markets
Psychedelic Stocks Jumped 10% Last Week
July 09, 2023
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly
Via
Talk Markets
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues
July 01, 2023
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up...
Via
Talk Markets
The 3 Best Psychedelic Stocks to Buy Now
June 29, 2023
Psychedelic stocks promise to bring therapeutics to market that were taboo until recently and have huge upside.
Via
InvestorPlace
MindMed Shareholders Vote For All Six Company Nominees At Annual Meeting, Current R&D Path Upheld
June 27, 2023
MindMed’s (NASDAQ: MNMD) heated proxy battle over R&D strategy might finally be coming to an end.
Via
Benzinga
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue
June 17, 2023
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.
Via
Talk Markets
Major Psychedelic Compound-Based Research & Development Stocks: June Update
June 10, 2023
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index
Via
Talk Markets
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
June 09, 2023
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr.
Via
Benzinga
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
June 05, 2023
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud
Via
Benzinga
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
June 01, 2023
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.
Via
Talk Markets
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
May 31, 2023
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...
Via
Benzinga
MindMed And FCM Holdings' Dispute Over Clinical Path Forward Deepens
May 30, 2023
The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis...
Via
Benzinga
MindMed Calls FDA Experts To Validate LSD Drug Development Strategy
May 25, 2023
In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, t
Via
Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
May 23, 2023
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...
Via
Benzinga
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
May 19, 2023
MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.
Via
Benzinga
FCM Holdings Accuse MindMed Braintrust Of 'Pursuing Misguided Clinical Path for MM-120'
May 16, 2023
Mind Medicine (NASDAQ: MNMD) activist shareholders FCM MM Holdings are at it again.
Via
Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
May 08, 2023
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Via
Benzinga
MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections
May 05, 2023
Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.